JP2021521822A5 - - Google Patents
Info
- Publication number
- JP2021521822A5 JP2021521822A5 JP2020559408A JP2020559408A JP2021521822A5 JP 2021521822 A5 JP2021521822 A5 JP 2021521822A5 JP 2020559408 A JP2020559408 A JP 2020559408A JP 2020559408 A JP2020559408 A JP 2020559408A JP 2021521822 A5 JP2021521822 A5 JP 2021521822A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- subunit
- linker segment
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024197045A JP2025032113A (ja) | 2018-04-25 | 2024-11-11 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810376920.1 | 2018-04-25 | ||
| CN201810376920.1A CN110396133B (zh) | 2018-04-25 | 2018-04-25 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| PCT/US2019/028933 WO2019209965A2 (en) | 2018-04-25 | 2019-04-24 | Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197045A Division JP2025032113A (ja) | 2018-04-25 | 2024-11-11 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521822A JP2021521822A (ja) | 2021-08-30 |
| JP2021521822A5 true JP2021521822A5 (enExample) | 2022-05-02 |
Family
ID=68294664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559408A Pending JP2021521822A (ja) | 2018-04-25 | 2019-04-24 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
| JP2024197045A Pending JP2025032113A (ja) | 2018-04-25 | 2024-11-11 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197045A Pending JP2025032113A (ja) | 2018-04-25 | 2024-11-11 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12473337B2 (enExample) |
| JP (2) | JP2021521822A (enExample) |
| KR (1) | KR20210024446A (enExample) |
| CN (2) | CN110396133B (enExample) |
| AU (1) | AU2019261411B2 (enExample) |
| BR (1) | BR112020021791A2 (enExample) |
| CA (1) | CA3097995A1 (enExample) |
| EA (1) | EA202092459A1 (enExample) |
| WO (1) | WO2019209965A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| JP7682150B2 (ja) * | 2019-07-25 | 2025-05-23 | ザ・ユニバーシティ・オブ・シカゴ | プロテアーゼ活性化治療剤を含む組成物および方法 |
| JP7767290B2 (ja) | 2020-01-11 | 2025-11-11 | アスクジーン・ファーマ・インコーポレイテッド | 新規なマスクされたサイトカインおよびその使用方法 |
| CN115734806A (zh) * | 2020-04-01 | 2023-03-03 | 西里欧发展公司 | 掩蔽的il-12细胞因子和其切割产物 |
| JP2023553323A (ja) * | 2020-11-25 | 2023-12-21 | エクシリオ デベロップメント， インコーポレイテッド | 腫瘍特異的に切断可能なリンカー |
| CN116601175A (zh) * | 2020-12-18 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 用于靶向疗法的前体蛋白和试剂盒 |
| EP4314073A4 (en) * | 2021-03-24 | 2025-02-19 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| JP2024516610A (ja) * | 2021-04-21 | 2024-04-16 | キュー バイオファーマ， インコーポレイテッド | Ｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 |
| CA3226924A1 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| EP4419545A4 (en) | 2021-10-20 | 2025-10-22 | Synthekine Inc | HETERODIMERIC FC CYTOKINES AND THEIR USES |
| IL322055A (en) * | 2023-01-13 | 2025-09-01 | Regeneron Pharma | IL12 receptor agonists and methods of using them |
| AU2024251934A1 (en) | 2023-04-12 | 2025-10-30 | Shanghai Kangabio Co., Limited | Multifunctional molecules comprising masked interleukin 12 and methods of use |
| TW202523680A (zh) * | 2023-12-07 | 2025-06-16 | 大陸商上海藥明生物技術有限公司 | 針對ｉｌ－１２受體的異二聚體蛋白 |
| WO2025256578A1 (zh) * | 2024-06-12 | 2025-12-18 | 龙启生物制药(杭州)有限公司 | Treg细胞靶向IL12融合蛋白及其制备、治疗方法 |
| WO2026020161A1 (en) * | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| WO1997020062A1 (en) * | 1995-12-01 | 1997-06-05 | University Of Massachusetts | Il-12 p40 subunit fusion polypeptides and uses thereof |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| PT1037927E (pt) * | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP1418184A1 (en) * | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| JP4718274B2 (ja) | 2005-08-25 | 2011-07-06 | 東京エレクトロン株式会社 | 半導体製造装置，半導体製造装置の流量補正方法，プログラム |
| US8242081B2 (en) | 2005-12-06 | 2012-08-14 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| RU2689160C2 (ru) * | 2014-02-19 | 2019-05-24 | Мерк Патент Гмбх | Противораковая таргетная иммунотерапия с применением il-12 |
| CN105543279A (zh) * | 2014-10-30 | 2016-05-04 | 常州卡斯比生物科技有限公司 | 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂 |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| CN105218682B (zh) * | 2015-10-26 | 2019-05-07 | 杨晶 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
| EP3184548A1 (en) * | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| WO2018030806A1 (ko) * | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| KR102050463B1 (ko) * | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
-
2018
- 2018-04-25 CN CN201810376920.1A patent/CN110396133B/zh active Active
-
2019
- 2019-04-24 WO PCT/US2019/028933 patent/WO2019209965A2/en not_active Ceased
- 2019-04-24 AU AU2019261411A patent/AU2019261411B2/en active Active
- 2019-04-24 KR KR1020207033158A patent/KR20210024446A/ko not_active Ceased
- 2019-04-24 CA CA3097995A patent/CA3097995A1/en active Pending
- 2019-04-24 BR BR112020021791-3A patent/BR112020021791A2/pt unknown
- 2019-04-24 EA EA202092459A patent/EA202092459A1/ru unknown
- 2019-04-24 US US17/049,021 patent/US12473337B2/en active Active
- 2019-04-24 JP JP2020559408A patent/JP2021521822A/ja active Pending
- 2019-04-24 CN CN201980042842.4A patent/CN112638938A/zh active Pending
-
2024
- 2024-11-11 JP JP2024197045A patent/JP2025032113A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032113A5 (enExample) | ||
| JP2023506454A5 (enExample) | ||
| JP2021522786A5 (enExample) | ||
| Kazane et al. | Self-assembled antibody multimers through peptide nucleic acid conjugation | |
| JP2023520517A5 (enExample) | ||
| TWI250988B (en) | Thrombopoietic compounds | |
| Stork et al. | A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G | |
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| JP2023518518A5 (enExample) | ||
| JP2021515599A5 (enExample) | ||
| JP2021530243A5 (enExample) | ||
| JP2020508691A5 (enExample) | ||
| JP2018138588A (ja) | 新規リンカー、その製造方法およびその応用 | |
| KR20050003400A (ko) | 시토킨과 종양 표적화 단백질의 융합물 | |
| KR20050007359A (ko) | 종양 치료를 위한 면역접합체 | |
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| JP6876618B2 (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| JP2008535475A5 (enExample) | ||
| JPH10509723A (ja) | 免疫応答の調節 | |
| JP2022548364A5 (enExample) | ||
| Westerberg et al. | Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells | |
| JP2022528053A5 (enExample) | ||
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| AU7526196A (en) | Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands | |
| RU2003129163A (ru) | Полинуклеотид, который можно использовать для модулирования пролиферации раковых клеток |